Eli Lilly vs. Novo Nordisk: Assessing Market Leadership and Valuation in the GLP-1 Weight Loss Boom

The GLP-1 receptor agonist market has become a defining battleground in the obesity and diabetes drug sector, with Eli Lilly and Novo Nordisk locked in a high-stakes race to dominate a rapidly expanding industry. As of late 2025, both companies have solidified their positions through innovative pipelines and aggressive commercial strategies, but their trajectories diverge sharply in terms of market share, revenue growth, and valuation dynamics. This analysis examines their strategic positioning and financial metrics to determine which firm is better poised to lead the next phase of the GLP-1 revolution.

Market Leadership: Lilly's Dominance and Novo's Resilience

Eli Lilly has emerged as the clear front-runner in the U.S. GLP-1 market, capturing 58% of total prescriptions in Q3 2025 compared to Novo Nordisk's 42%. This dominance is driven by the superior efficacy of Lilly's dual-agonist drugs, particularly Zepbound, which demonstrated a 20% average weight loss over 72 weeks-outpacing Wegovy's 13.7%. The commercial success of Zepbound and Mounjaro has translated into explosive revenue growth: combined sales of $25 billion in Q3 2025, with Zepbound alone generating $3.6 billion and Mounjaro $6.5 billion. By contrast, Novo's Wegovy and Ozempic reported $3.1 billion and $4.7 billion in sales, respectively, reflecting slower growth despite their early market entry.

Lilly's leadership is further reinforced by its pipeline of oral GLP-1 drugs. While Novo Nordisk secured FDA approval for an oral Wegovy variant slated for 2026, Lilly's orforglipron offers a key differentiator: it does not require patients to fast before administration, a convenience factor that could drive adoption. Analysts project Lilly's revenue to reach $94.3 billion by 2027, with 2025 serving as a critical inflection point. Novo, meanwhile, faces headwinds including supply constraints and competition from compounded versions of its drugs, which have contributed to a 53% stock price decline over the past year.

Valuation Dynamics: High Multiples for Growth vs. Discounted Value

The divergent trajectories of these two giants are reflected in their valuation metrics. Eli Lilly trades at a P/E ratio of 52 and a P/S ratio of approximately 15.41 as of November 2025, reflecting investor confidence in its high-margin GLP-1 franchise and broader pipeline diversification. This premium valuation is justified by Lilly's 53.9% revenue growth and 480% net income growth in Q3 2025, as well as its historic $1 trillion market capitalization. In contrast, Novo Nordisk's P/E ratio of 14 and P/S ratio of 5.31 according to market data suggest a more conservative valuation, despite its leadership in semaglutide-based therapies.

The disparity in multiples highlights a key strategic question: Is Lilly's high valuation warranted by its growth potential, or does Novo's discounted price represent a value opportunity? Lilly's P/S ratio, while elevated, aligns with its market-leading position and robust cash flow generation. Novo's lower P/S ratio, meanwhile, reflects challenges such as supply bottlenecks and pricing pressures, but also offers a margin of safety for investors willing to bet on its long-term pipeline in metabolic diseases.

Future Outlook: Navigating the Oral GLP-1 Transition

The next phase of the GLP-1 market will hinge on the adoption of oral formulations, a segment both companies are aggressively targeting. Novo's first-mover advantage with oral Wegovy could provide a temporary edge, but Lilly's orforglipron-expected to launch in 2026-may offset this with its user-friendly dosing. Analysts estimate that oral GLP-1 drugs could capture 30% of the market by 2027, making this segment a critical battleground.

For Lilly, the path to $94.3 billion in revenue by 2027 depends on maintaining its current growth trajectory while mitigating risks such as pricing negotiations with insurers and potential generic competition. Novo, on the other hand, must address its supply limitations and reaccelerate growth to avoid further erosion of market share. Both companies also face regulatory scrutiny over pricing practices, which could impact their long-term margins.

Conclusion: A Tale of Two Strategies

Eli Lilly and Novo Nordisk represent two distinct investment theses in the GLP-1 space. Lilly's aggressive innovation, market leadership, and premium valuation position it as the growth story of the sector, albeit with higher risk due to its elevated multiples. Novo Nordisk, while facing near-term challenges, offers a more conservative bet with a discounted valuation and a diversified pipeline in metabolic diseases. For investors, the choice between these two titans will depend on their appetite for growth versus value-and their confidence in which company can best navigate the evolving dynamics of the obesity drug market.